MedTrace Logo

Essential Oils for Enhancing QOL in ASD

NCT02543203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-04-01

Study results available
· View outcomes & findings →

Summary

Essential oils (aromatic oils extracted from plant parts) are routinely used by the public and are available on the market. Investigators are conducting this study because it is unknown whether the essential oils formulations will be safe and effective for improving quality of life in children with Autism Spectrum Disorder (ASD) by helping them relax and sleep.

Children invited to participate in this study must be between 3-9 years of age and have been diagnosed with Autism Spectrum Disorder. Twenty eight children and their families will be enrolled in the study.

Participants will try two different fragrant oils in a double-blind randomized order. Each child will receive each treatment for 3 months, with a 1-month "washout" period in between during which no oil is used.

Conditions

Interventions

BIOLOGICAL

Reconnect

Topical Essential Oils mixture and aromatic method

BIOLOGICAL

Coconut oil Comparator

Topical Essential Oils mixture and aromatic method

Sponsors & Collaborators

  • Young Living Essential Oils

    collaborator UNKNOWN

  • Jill Hollway

    lead OTHER

Principal Investigators

  • Jill A Hollway, Ph.D., M.A. · Ohio State University, Nisonger Center UCEDD

  • Eugene Arnold, M.D.,M.A. · Ohio State University, Nisonger Center UCEDD

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-03-16
Completion
2018-03-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02543203 on ClinicalTrials.gov